Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)

Core Insights - Argo Biopharmaceutical Co., Ltd. has initiated a global Phase 2b clinical trial for DII235 (BW-20829) in adults with elevated Lipoprotein (a) and Atherosclerotic Cardiovascular Disease, marking a significant advancement in its clinical pipeline [1][2] - The company will receive milestone payments from Novartis as part of their collaboration, which will support ongoing research and development of its siRNA portfolio [1] - BW-20829 is the sixth asset in Argo's pipeline to enter mid-stage global clinical development, highlighting the company's progress in RNAi therapeutics [1][3] Company Overview - Argo Biopharma is focused on developing next-generation RNAi therapeutics aimed at providing improved treatment options for various diseases, including cardiovascular diseases, viral infections, and metabolic conditions [3] - The company has established a diverse pipeline with six RNAi candidates currently in clinical development, showcasing its commitment to addressing unmet medical needs [3]